<DOC>
	<DOCNO>NCT00815516</DOCNO>
	<brief_summary>The study evaluate effective safe drug micafungin compare drug amphotericin B deoxycholate treating neonate young infant certain fungal infection .</brief_summary>
	<brief_title>Study Compare Efficacy Safety Micafungin Versus Conventional Amphotericin B Treatment Neonatal Candidiasis</brief_title>
	<detailed_description>Neonates young infant stratify estimate gestational age world region</detailed_description>
	<mesh_term>Candidiasis</mesh_term>
	<mesh_term>Micafungin</mesh_term>
	<mesh_term>Amphotericin B</mesh_term>
	<mesh_term>Liposomal amphotericin B</mesh_term>
	<mesh_term>Echinocandins</mesh_term>
	<mesh_term>Amphotericin B , deoxycholate drug combination</mesh_term>
	<mesh_term>Deoxycholic Acid</mesh_term>
	<criteria>Infant great 48 hour life birth day life 120 time culture acquisition Diagnosis proven invasive candidiasis within 4 day prior study start Subject 's parent legal guardian agrees allow subject participate another study another investigational drug treatment . Infant history hypersensitivity severe vasomotor reaction echinocandin systemic amphotericin B product Infant receive 48 hour systemic antifungal therapy prior first dose study drug Infant breakthrough systemic fungal infection receive amphotericin B product echinocandin prophylaxis Infant fail prior systemic antifungal therapy episode invasive candidiasis Infant coinfected nonCandida fungal organism Infant whose positive yeast culture solely indwell bladder catheter ( unless obtain time indwell catheter place ) sputum . Infant previously enrol study</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>120 Days</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>candidiasis</keyword>
	<keyword>candida</keyword>
	<keyword>Neonate</keyword>
	<keyword>candidemia</keyword>
	<keyword>Micafungin</keyword>
	<keyword>Mycamine</keyword>
	<keyword>amphotericin B deoxycholate</keyword>
</DOC>